Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc. (PFE) Stock Price & Market Analysis
PFE · NYSE · Pharmaceuticals
$27.80
▼ -$0.3200(-1.14%)4:01 PM ET - vs previous closeQuote as of Oct 2, 2026, 4:01 PM EDT
Regular-session close · Oct 2, 2026, 4:01 PM EDT.
Yahoo Finance · delayed, minutes not stated · as of Oct 2, 2026, 4:01 PM EDT · current source
Long-term rangesAvailable historyHide
Price history: 2000-10-04–2026-10-02. Earlier trading may not be included. Highs and lows use intraday prices when available, otherwise closing prices. The 52-week range is reported separately by Yahoo Finance.
Loading price chart…
Data dates
PriceAt closeLast traded
FundamentalsLast checked
AnalystLast checked
Loading upcoming events…
Reported fundamentals
PFE financial overview
Annual revenue
USD 62.58B
Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.
Revenue change
-1.6%
Change versus the fiscal year ended Dec 31, 2024.
Net profit margin
12.4%
Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.
These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.
Company · Profile
About Pfizer Inc. (PFE)
Sector, leadership, and how Pfizer Inc. earns its revenue.
Healthcare
Company · Profile
About Pfizer Inc. (PFE)
Sector, leadership, and how Pfizer Inc. earns its revenue.
Pfizer Inc.
NYSE · PFE · US
Company overview as of Oct 5, 2026.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Headquarters
- New York, NY, United States
- Country
- US
- Founded
- 1849
- Employees
- 75,000
- CEO
- Dr. Albert Bourla D.V.M., Ph.D.
- Exchange
- NYSE
Business model & operating evidence
AI business exposure
- Revenue exposure
- AI-specific revenue is not separated in the available company statements.
- Capital-spending dependency
- No reviewed quantitative dependency model is available.
- Compute role
- See the sourced business description; AI labels do not establish compute revenue.
- Platform examples
- An exhaustive, consistently defined product inventory is unavailable.
- Ecosystem links
- Supplier and customer links require reviewed disclosures.
Narrative versus numbers
Demand is expanding
Supporting observation: 2.6%
Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · SEC Companyfacts · 2026-06-28
Growth produces accounting profit
Supporting observation: 6.8%
Reported-period net margin. A positive figure supports accounting profitability, not cash generation. · SEC Companyfacts · 2026-10-05T08:53:31.834Z
The business generates cash after investment
Supporting observation: USD 302M
Latest reported free cash flow. It is not a forecast and may cover a different period from the fiscal-year figures above. · SEC Companyfacts · 2026-06-28
These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.
Operating measures
- Revenue
- $15.03Bquarter ended Jun 28, 2026
- EPS
- -$0.04quarter ended Jun 28, 2026
- Capital expenditure
- $533.00Mquarter ended Jun 28, 2026
- Free cash flow
- $302.00Mquarter ended Jun 28, 2026
- Free cash flow margin
- 2.0%quarter ended Jun 28, 2026
- Revenue growth year over year
- 2.6%quarter ended Jun 28, 2026
Leadership
Chief executive officerDr. Albert Bourla D.V.M., Ph.D.
Source: Yahoo Finance · Oct 5, 2026
Ownership filings and insider activityCompetitors & comparisons
Loading competitor research…
Loading fund exposure…
Governance & sustainability
All data sources
Search the dated figures used for this view. Each entry identifies its units, reporting period and calculation status.
Premarket
Regular hours: 9:30 AM–4:00 PM America/New_York
Next open: 2026-10-05 · 9:30 AM America/New_York
Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.
Shortcuts
With research tools focused: / search · W watchlist · C compare · F financials · E earnings · N news · T technicals · Esc close